PAXMEDICA INC (PXMD) Stock Price, Forecast & Analysis
USA - NASDAQ:PXMD - US70424C2035 - Common Stock
PXMD Key Statistics, Chart & Performance
The current stock price of PXMD is 0.6883 USD. In the past month the price increased by 27.7%. In the past year, price decreased by -97.28%.
PXMD Latest News, Press Relases and Analysis
PXMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.96 | 935.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.67 | 466.81B | ||
| MRK | MERCK & CO. INC. | 10.32 | 227.17B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.43 | 99.17B | ||
| ZTS | ZOETIS INC | 18.95 | 53.23B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 22.72B | ||
| VTRS | VIATRIS INC | 4.81 | 13.06B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.81 | 11.36B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.78 | 8.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.63 | 4.09B |
Related stock screener links
About PXMD
Company Profile
PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
Company Info
PAXMEDICA INC
303 South Broadway, Suite 125
Tarrytown NEW YORK US
Employees: 3
Phone: 19149872876
PAXMEDICA INC / PXMD FAQ
What does PAXMEDICA INC do?
PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
What is the stock price of PAXMEDICA INC today?
The current stock price of PXMD is 0.6883 USD. The price decreased by -7.61% in the last trading session.
Does PXMD stock pay dividends?
PXMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of PXMD stock?
PXMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for PAXMEDICA INC?
PAXMEDICA INC (PXMD) has a market capitalization of 5.10M USD. This makes PXMD a Nano Cap stock.
Who owns PAXMEDICA INC?
You can find the ownership structure of PAXMEDICA INC (PXMD) on the Ownership tab.
PXMD Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PXMD. When comparing the yearly performance of all stocks, PXMD is a bad performer in the overall market: 88.21% of all stocks are doing better.
PXMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PXMD. PXMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PXMD Financial Highlights
Over the last trailing twelve months PXMD reported a non-GAAP Earnings per Share(EPS) of -15.85. The EPS increased by 23.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -321.98% | ||
| ROE | -540.3% | ||
| Debt/Equity | 0 |
PXMD Forecast & Estimates
null analysts have analysed PXMD and the average price target is 3.06 USD. This implies a price increase of 344.57% is expected in the next year compared to the current price of 0.6883.